Why Sarepta Therapeutics' Q3 Was Better Than Expected

Sarepta Therapeutics (NASDAQ: SRPT) was once a high-flying biotech stock. That was before the Food and Drug Administration (FDA) surprisingly rejected approval of the Duchenne muscular dystrophy (DMD) drug golodirsen in August.